Which AREDS is best for macular degeneration?

Vitamins can help certain patients with age-related macular degeneration (AMD) decrease their risk of losing central vision….The AREDS2 Formula

• lutein 10 milligrams (mg)
• zeaxanthin 2mg.
• vitamin C 500mg.
• vitamin E 400IU.
• zinc oxide 80mg or 25mg (these two doses worked equally well), and.
• cupric oxide 2mg.

Should you take AREDS2 if you don’t have macular degeneration?

AREDS2 enrolled 4,203 participants, ages 50-85. Because the original AREDS trial established that the formulation does not benefit people with no AMD or early AMD, the AREDS2 trial was limited to people with intermediate AMD in both eyes, or intermediate AMD in one eye and advanced AMD in the other eye.

Who should not take Preservision Areds 2?

Who should not take PRESERVISION AREDS 2?

• a high amount of oxalic acid in urine.
• iron metabolism disorder causing increased iron storage.
• sickle cell anemia.
• anemia from pyruvate kinase and G6PD deficiencies.
• decreased blood-clotting from low vitamin K.
• increased risk of bleeding due to clotting disorder.

What are the findings of the AREDS 2 study?

Dr. Emily Chew, presenting the AREDS2 findings at ARVO, pointed out that study participants were very well-nourished, and suggested that a greater reduction in AMD progression may have been demonstrated if the subjects’ diets had been more representative of the general U.S. population.

Who are the manufacturers of AREDS and AREDS2?

Bausch & Lomb produced the formulations for the AREDS and AREDS2 trials. The NEI cannot comment on the safety or effectiveness of any specific brand’s formulations. What are lutein, zeaxanthin, and beta-carotene?

Who are excluded from AREDS and AREDS2?

AREDS2 included only people with intermediate AMD in both eyes or intermediate AMD in one eye and advanced AMD in the other eye. AREDS2 excluded people without AMD or with early AMD because AREDS data showed no benefit for these individuals.

What was the effect of AREDS on advanced AMD?

In the AREDS trial, taking the AREDS formula reduced the risk of advanced AMD by about 25% over a five-year period. In the AREDS2 trial, adding omega-3s or lutein + zeaxanthin to the AREDS formulation (containing beta-carotene) had no additional overall effect on the risk of advanced AMD.